Replies to post #11752 on IntelGenx Technologies Corp (IGXT)

[Tasso9]

On April 13, 2017, RedHill, together with IntelGenx Corp. (IGX.V) (IGXT) ("IntelGenx"), announced that the Ministry of Health of Luxembourg had granted national marketing authorization for RIZAPORT® (5 mg and 10 mg). The national marketing authorization was granted in Luxembourg on the basis of the European Decentralized Procedure (DCP), in which Luxembourg served as the Concerned Member State. The approval in Luxembourg marks the completion of the current marketing approval process for RIZAPORT® under the European DCP.